Meridian Bioscience (VIVO) Reports In-Line Q3 EPS, Miss on Revenues; Affirms Fiscal 2018 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Meridian Bioscience Reports Third Quarter 2018 Operating Results, Declares Regular Third Quarter Cash Dividend, and Reaffirms Fiscal 2018 Guidance
July 31, 2018 7:30 AM EDTCINCINNATI, July 31, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today:
GENERAL HIGHLIGHTS
Reported record fiscal 2018 third quarter and first nine months net revenues of $51.7 million and $160.5 million, respectively, increases of 3% and 6%, respectively, from the same periods of the prior fiscal year;Â reported third quarter operating income of $8.7 million (including $2.1 million of costs associated with executive transition and realignment, and litigation), an increase of 103% from the same period of the prior fiscal year, which included a $6.6 million non-cash goodwill impairment charge;Â reported nine months operating income of $24.5 million... More